Matinas BioPharma amends CEO Jabbour's employment agreement extending retention bonus window to June 30, 2026

Matinas BioPharma Holdings, Inc.

Retention bonus trigger extended from Mar 31, 2026 to Jun 30, 2026; 2/3 paid upon signing definitive agreement, 1/3 at closing.
CEO guaranteed 2025 annual bonus at target, payable by Feb 1, 2026, subject to continued employment.
Change in Control definition expanded to include material change to primary business.
Cause and Good Reason definitions modified; company confirms no grounds for Cause exist as of Dec 12, 2025.
Company to reimburse CEO up to $20,000 for legal fees incurred for amendment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.